Author: Díaz, Lilián ; Ranero, Sabrina ; Silveira, Gonzalo ; Perdomo, Susana ; Menyou, Alba ; Brugnini, Andreina ; Trias, Natalia ; Grille, Sofía ; Lens, Daniela

AbstractBackgroundEndothelial progenitor cells (EPCs) are immature cells able to proliferate and contribute to endothelial repair, vascular homeostasis, neovascularization, and angiogenesis. It therefore seems likely that circulating EPCs have therapeutic potential in ischemic and vascular diseases. In this study we evaluated the efficiency of EPC mobilization and collection by large volume leukapheresis in subjects with hematological diseases, treated with plerixafor in association with G‐CSF.MethodsTwenty‐two patients with lymphoid malignancies underwent rHuG‐CSF and plerixafor treatment followed by leukapheresis. Blood samples before and after treatment and apheresis liquid sample were taken and analyzed by flow cytometry in order to quantified EPC.ResultsThe percentage of CD34+ cells and EPCs among circulating total nuclear cells (TNCs) increased significantly by approximately 2‐fold and 3‐fold, respectively, after plerixafor treatment. Consequently, the absolute number of CD34+ cells and EPCs were increased 4‐fold after plerixafor treatment. The median PB concentration of EPCs before and after treatment were 0.77/μL (0.31‐2.15) and 3.41/μL (1.78‐4.54), respectively, P < .0001. The total EPCs collected per patient were 3.3×107 (0.8×107–6.8×107).ConclusionWe have shown that plerixafor in combination with G‐CSF allows the mobilization and collection of large amounts of EPCs along with CD34+ cells in lymphoid neoplasm patients. The possibility to collect and to store these cells could represent a promising therapeutic tool for the treatment of ischemic complications without the need of in vitro expansion.

02 Nov 2021·International Journal of Radiation BiologyQ4 · MEDICINE

Radiation countermeasures for hematopoietic acute radiation syndrome: growth factors, cytokines and beyond

Q4 · MEDICINE

Article

Author: Singh, Vijay K. ; Seed, Thomas M.

PURPOSEThe intent of this article is to report the status of some of the pharmaceuticals currently in late stage development for possible use for individuals unwantedly and acutely injured as a result of radiological/nuclear exposures. The two major questions we attempt to address here are: (a) What medicinals are currently deemed by regulatory authorities (US FDA) to be safe and effective and are being stockpiled? (b) What additional agents might be needed to make the federal/state/local medicinal repositories more robust and useful in effectively managing contingencies involving radiation overexposures?CONCLUSIONSA limited number (precisely four) of medicinals have been deemed safe and effective, and are approved by the US FDA for the 'hematopoietic acute radiation syndrome (H-ARS).' These agents are largely recombinant growth factors (e.g. rhuG-CSF/filgrastim, rhuGM-CSF/sargramostim) that target and stimulate myeloid progenitors within bone marrow. Romiplostim, a small molecular agonist that enhances platelet production via stimulation of bone marrow megakaryocytes, has been recently approved and indicated for H-ARS. It is critical that additional agents for other major sub-syndromes of ARS (gastrointestinal-ARS) be approved. Future success in developing such medicinals will undoubtedly entail some form of a polypharmaceutical strategy, or perhaps novel, bioengineered chimeric agents with multiple, radioprotective/radiomitigative functionalities.

01 Apr 2019·Veterinary MicrobiologyQ2 · AGRICULTURAL & FORESTRY SCIENCE

Use of recombinant canine granulocyte-colony stimulating factor to increase leukocyte count in dogs naturally infected by canine parvovirus

Q2 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Armenise, Andrea ; Cirone, Francesco ; Trerotoli, Paolo ; De Sario, Costantina ; Pratelli, Annamaria ; De Nitto, Anna ; Decaro, Nicola ; Bertazzolo, Walter

Canine parvovirus (CPV) is one of the most important cause of mortality in young dogs and no specific treatment exists. Since prolonged leukopenia greatly increases the risk of death in infected pups, strategies to counteract this decline were investigated. The outcomes of CPV naturally infected pups treated with the recombinant canine granulocyte-colony stimulating factor (rcG-CSF), in combination with the routine therapy, were compared with similarly-managed infected pups not treated with rcG-CSF. A non-randomized prospective clinical trial was performed on 62 CPV infected pups with WBC counts <3000 cells/μL and two different groups were selected based on a non-randomized approach. Group A dogs (31/62) received 5 μg/Kg of rcG-CSF daily from the hospitalization day until WBC reached the reference range (3-5 days) and group B (31/62) received 1 ml of placebo injection. All dogs in group A recovered, while five dogs in group B died. The rcG-CSF treatment demonstrated a statistically significant effect on WBC counts (p < 0.0001) and, surprisingly, also on lymphocytes and monocytes counts (p < 0.0001). There was no significant effect of treatment on neutrophil count (p = 0.5502). Although lymphocytes and monocytes are not a specific target for rcG-CSF, our study highlights that rcG-CSF is able to improve haematological parameters compared to untreated dogs and a clear increase in their number was detected, as previously described for humans treated with the homologous molecule.

100 Deals associated with Filgrastim biosimilar(Xiamen Amoytop Biotech Co. Ltd.)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L03AA02	-

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Neutropenia	CN	Xiamen Amoytop Biotech Co. Ltd.	01 Jan 1999

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis